文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

COVID-19与SARS及H1N1流感肺部组织病理学比较:系统综述

Lung Histopathology in Coronavirus Disease 2019 as Compared With Severe Acute Respiratory Sydrome and H1N1 Influenza: A Systematic Review.
PubMed 文献 · Chest · 2020-10-07
一句话结论COVID-19、SARS和H1N1流感肺部病理均以弥漫性肺泡损伤为主,但COVID-19和SARS微血栓报告率高于H1N1流感。

该系统综述纳入26篇COVID-19文献(171例)、20篇H1N1文献(287例)和8篇SARS文献(64例),比较三者的肺部组织病理学特征。结果显示,急性期弥漫性肺泡损伤(DAD)在COVID-19中报告率为88%,与H1N1(90%)和SARS(98%)相似。肺微血栓在COVID-19中报告率为57%,SARS为58%,均高于H1N1流感的24%。提示COVID-19和SARS的微血栓形成可能更常见,但需进一步验证其临床意义。

要点

  • COVID-19急性期DAD报告率为88%,与H1N1(90%)和SARS(98%)相似,支持DAD是ARDS的组织学相关表现。
  • 肺微血栓在COVID-19中报告率为57%,SARS为58%,均高于H1N1流感的24%。
  • 该系统综述纳入171例COVID-19、287例H1N1和64例SARS患者的尸检/活检病理资料。
  • 微血栓在COVID-19和SARS中更常见,但原文指出需未来工作验证该发现及其机制和临床关联。

适用人群与场景

  • 纳入文献报告的COVID-19、H1N1流感或SARS患者,接受病理检查(活检或尸检)者。
  • 原文未明确排除人群。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:系统综述,采用PRISMA-Individual Participant Data指南,检索MEDLINE和PubMed至2020年6月24日。
  • 纳入26篇COVID-19文献(171例)、20篇H1N1文献(287例)、8篇SARS文献(64例)。
  • 急性期DAD报告率:COVID-19为88%,H1N1为90%,SARS为98%。
  • 肺微血栓报告率:COVID-19为57%,SARS为58%,H1N1为24%。

证据类型、等级与局限

  • 证据类型:系统综述。
  • 原文未述局限性。

对床旁实践的改变

  • 原文结果提示COVID-19和SARS肺部病理中微血栓报告率高于H1N1流感,但原文未给出直接改变临床实践的建议。
  • 原文指出需未来工作验证该组织病理学发现,若被证实,需阐明机制并描述与临床重要结局的关联。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Patients with severe coronavirus disease 2019 (COVID-19) have respiratory failure with hypoxemia and acute bilateral pulmonary infiltrates, consistent with ARDS. Respiratory failure in COVID-19 might represent a novel pathologic entity.

RESEARCH QUESTION: How does the lung histopathology described in COVID-19 compare with the lung histopathology described in SARS and H1N1 influenza?

STUDY DESIGN AND METHODS: We conducted a systematic review to characterize the lung histopathologic features of COVID-19 and compare them against findings of other recent viral pandemics, H1N1 influenza and SARS. We systematically searched MEDLINE and PubMed for studies published up to June 24, 2020, using search terms for COVID-19, H1N1 influenza, and SARS with keywords for pathology, biopsy, and autopsy. Using PRISMA-Individual Participant Data guidelines, our systematic review analysis included 26 articles representing 171 COVID-19 patients; 20 articles representing 287 H1N1 patients; and eight articles representing 64 SARS patients.

RESULTS: In COVID-19, acute-phase diffuse alveolar damage (DAD) was reported in 88% of patients, which was similar to the proportion of cases with DAD in both H1N1 (90%) and SARS (98%). Pulmonary microthrombi were reported in 57% of COVID-19 and 58% of SARS patients, as compared with 24% of H1N1 influenza patients.

INTERPRETATION: DAD, the histologic correlate of ARDS, is the predominant histopathologic pattern identified in lung pathology from patients with COVID-19, H1N1 influenza, and SARS. Microthrombi were reported more frequently in both patients with COVID-19 and SARS as compared with H1N1 influenza. Future work is needed to validate this histopathologic finding and, if confirmed, elucidate the mechanistic underpinnings and characterize any associations with clinically important outcomes.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Hariri LP, North CM, Shih AR, et al. Lung Histopathology in Coronavirus Disease 2019 as Compared With Severe Acute Respiratory Sydrome and H1N1 Influenza: A Systematic Review. Chest. 2020. PMID: 33038391. doi:10.1016/j.chest.2020.09.259

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。